NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly
reduced liver fat content in a multicenter, randomized, double‐blind, placebo‐controlled …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction in
the Western world and is increasing owing to its close association with obesity and insulin …

In patients with compensated advanced chronic liver disease (cACLD), the presence of
clinically significant portal hypertension (CSPH) and varices needing treatment (VNT) bears …

The evaluation and follow up of liver fibrosis and cirrhosis have been traditionally performed
by liver biopsy. However, during the last 20 years, it has become evident that this “gold …

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of
chronic liver disease, and its prevalence is rising worldwide. The occurrence of non …

This review summarizes our current understanding of nonalcoholic fatty liver disease
(NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic
syndrome and the incidence of which is rising rapidly due to the increasing epidemic of …

In the last years new evidence has accumulated on nonalcoholic fatty liver disease (NAFLD)
challenging the paradigms that had been holding the scene over the previous 30 years …

Background & Aims The benefits of farnesoid X receptor (FXR) agonists in patients with non-
alcoholic steatohepatitis (NASH) have been validated, although improvements in efficacy …

AIM: To investigate the efficacy of exercise interventions on hepatic fat mobilization in non-
alcoholic fatty liver disease (NAFLD) patients. METHODS: Ovid-Medline, PubMed, EMBASE …